277 related articles for article (PubMed ID: 16443183)
1. Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment.
Leibson CL; Barbaresi WJ; Ransom J; Colligan RC; Kemner J; Weaver AL; Katusic SK
Ambul Pediatr; 2006; 6(1):45-53. PubMed ID: 16443183
[TBL] [Abstract][Full Text] [Related]
2. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
[TBL] [Abstract][Full Text] [Related]
3. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study.
Barbaresi WJ; Katusic SK; Colligan RC; Weaver AL; Jacobsen SJ
J Dev Behav Pediatr; 2007 Aug; 28(4):274-87. PubMed ID: 17700079
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
5. Symptoms of attention-deficit/hyperactivity disorder following traumatic brain injury in children.
Levin H; Hanten G; Max J; Li X; Swank P; Ewing-Cobbs L; Dennis M; Menefee DS; Schachar R
J Dev Behav Pediatr; 2007 Apr; 28(2):108-18. PubMed ID: 17435461
[TBL] [Abstract][Full Text] [Related]
6. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
Barner JC; Khoza S; Oladapo A
Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
[TBL] [Abstract][Full Text] [Related]
7. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy with atomoxetine for US children and adolescents.
Bhatara VS; Aparasu RR
Ann Clin Psychiatry; 2007; 19(3):175-80. PubMed ID: 17729019
[TBL] [Abstract][Full Text] [Related]
9. Prescribed stimulant use by Western Australians with Attention Deficit Hyperactivity Disorder (ADHD): does amount dispensed exceed the expected authorised use?
Calver J; Sanfilippo F; Preen D; Bulsara M
Aust N Z J Public Health; 2007 Dec; 31(6):533-9. PubMed ID: 18081573
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and characteristics of emergency departments visits by US adults with psychiatric disorder and antipsychotic mention from 2000 to 2004.
Sankaranarayanan J; Puumala SE
Curr Med Res Opin; 2007 Jun; 23(6):1375-85. PubMed ID: 17594776
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003.
Sankaranarayanan J; Puumala SE; Kratochvil CJ
Curr Med Res Opin; 2006 Aug; 22(8):1475-91. PubMed ID: 16870073
[TBL] [Abstract][Full Text] [Related]
12. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder.
Visser SN; Lesesne CA; Perou R
Pediatrics; 2007 Feb; 119 Suppl 1():S99-106. PubMed ID: 17272592
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
14. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
15. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.
Birnbaum HG; Kessler RC; Lowe SW; Secnik K; Greenberg PE; Leong SA; Swensen AR
Curr Med Res Opin; 2005 Feb; 21(2):195-206. PubMed ID: 15801990
[TBL] [Abstract][Full Text] [Related]
16. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments.
Stein MA
Am J Manag Care; 2004 Jul; 10(4 Suppl):S89-98. PubMed ID: 15352535
[TBL] [Abstract][Full Text] [Related]
17. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
[TBL] [Abstract][Full Text] [Related]
18. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
[TBL] [Abstract][Full Text] [Related]
19. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
20. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
